StockData
Beta Bionics, Inc. logo

Beta Bionics, Inc. (BBNX) shareholders

BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 11/304% below fair value
$14.72−0.49 (-3.22%)

Close on Nov 17, 2026Market cap $800.28MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
88.2%
48M of 54M shares
Institutional holders
134
30 new, 23 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
0 buys · 56 sales
Net sold $5.58M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
T. Rowe Price Associates, Inc.8,943,06116.60%13G (passive)Sep 30, 2026
Robin C. John
Joint filing with Eventide Asset Management, LLC (13.40%), Finny Kuruvilla, M.D., Ph. D. (13.40%)
5,945,48813.40%13G (passive) amendmentMar 31, 2026
Eventide Asset Management, LLC
Joint filing with Finny Kuruvilla, M.D., Ph. D. (11.32%), Robin C. John (11.32%)
4,857,04111.32%13G (passive)Jan 31, 2025
Levy Guy
Joint filing with Soleus Capital Management, L.P. (8.60%), Soleus GP, LLC (8.60%) and 3 more
4,828,6198.70%13G (passive) amendmentSep 30, 2026
Spokes, Andrew J. M.
Joint filing with Dapice Joshua J. (9.90%), Dreyfuss, Philip D. (9.90%) and 14 more
4,379,9209.90%13G (passive) amendmentDec 31, 2025
Wehrly, Mark C.
Joint filing with Dapice Joshua J. (9.90%), Dreyfuss, Philip D. (9.90%) and 16 more
4,313,9209.90%13G (passive) amendmentSep 30, 2025
Saito Edric C.
Joint filing with Dapice Joshua J. (9.70%), Dreyfuss, Philip D. (9.70%) and 16 more
4,203,9209.70%13G (passive) amendmentJun 30, 2025
Wellington Management Group LLP
Joint filing with Wellington Group Holdings LLP (9.00%), Wellington Investment Advisors Holdings LLP (9.00%) and 1 more
3,901,5999.00%13G (passive)Mar 31, 2025
Soleus Capital Management, L.P.
Joint filing with Guy Levy (8.80%), Soleus GP, LLC (8.80%)
3,795,3418.80%13G (passive)Mar 31, 2025
Morgan Stanley
Joint filing with Morgan Stanley Capital Services LLC (7.80%)
3,739,5678.60%13G (passive) amendmentSep 30, 2025
Short Daniel S.
Joint filing with Dapice Joshua J. (8.10%), Dreyfuss, Philip D. (8.10%) and 14 more
3,607,9208.10%13G (passive) amendmentMar 31, 2026
Sands Capital Alternatives, LLC
Joint filing with Sands Frank M. (8.20%), Sands Capital Life Sciences Pulse Fund II. L.P. (8.20%)
3,570,1138.20%13G (passive) amendmentJun 30, 2025
RTW Investments, LP
Joint filing with Roderick Wong, M.D. (7.60%)
3,299,8697.60%13G (passive)Mar 31, 2025
Frank M. Sands
Joint filing with Sands Capital Life Sciences Pulse Fund II. L.P. (7.30%), Sands Capital Ventures, LLC (7.30%)
3,154,4097.30%13G (passive)Apr 2, 2025
Divisadero Street Capital, LLC
Joint filing with Divisadero Street Capital Management, LP (6.90%), William Zolezzi (6.90%) and 2 more
3,072,9856.90%13G (passive)Jul 17, 2026
BlackRock, Inc.2,778,7646.40%13G (passive)Sep 30, 2025
Guy Levy
Joint filing with Soleus Capital Management, L.P. (5.70%), Soleus GP, LLC (5.70%)
2,534,5655.80%13G (passive) amendmentDec 31, 2025
Point72 Capital Advisors, Inc.
Joint filing with Point72 Asset Management, L.P. (5.20%), Steven A. Cohen (5.20%)
2,290,0235.20%13G (passive)Feb 18, 2026
Israel A. Englander
Joint filing with Millennium Group Management LLC (5.30%), Millennium Management LLC (5.30%)
2,286,7285.30%13G (passive)Sep 15, 2025
Perceptive Advisors LLC
Joint filing with Joseph Edelman (5.10%), Perceptive Life Sciences Master Fund, Ltd. (5.10%)
2,203,8405.10%13G (passive)Mar 31, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of BBNXValueChange% of portfolio
Eventide Asset Management, LLC6,253,67311.50%$98.05M+308,1851.31%
Soleus Capital Management, L.P.4,393,7148.08%$68.85M+39,2132.37%
Morgan Stanley4,266,8227.85%$66.86M+39,1880.00%
Sands Capital Ventures, LLC3,708,0436.82%$58.11M–9.47%
BlackRock, Inc.3,340,1716.14%$52.34M+301,5760.00%
Point72 Asset Management, L.P.2,254,6834.15%$35.33M−270,3570.04%
Vanguard Capital Management LLC1,782,3463.28%$27.93M+54,3690.00%
Vestal Point Capital, LP1,600,0002.94%$25.07M−611,5180.59%
Rtw Investments, LP1,500,0002.76%$23.51M−500,0000.20%
Deerfield Management Company, L.P. (Series C)1,324,0002.44%$20.75M–0.22%
Omega Fund Management, LLC1,316,1832.42%$20.62M–11.11%
Eversept Partners, LP1,249,4412.30%$19.58M−165,3971.02%
Divisadero Street Capital Management, LP1,113,8022.05%$17.45MNew0.40%
Geode Capital Management, LLC1,073,4521.97%$16.82M+140,7740.00%
State Street Corp970,1921.78%$15.20M+24,1050.00%
Millennium Management LLC956,2441.76%$14.98M+95,3780.01%
Balyasny Asset Management L.P.855,6821.57%$13.41M+237,7670.02%
Perceptive Advisors LLC832,9441.53%$13.05M−10,0000.20%
JPMorgan Chase & Co703,3561.29%$11.96M+396,1270.00%
Bruce & Co., Inc.665,7001.22%$10.43M+115,0002.82%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202613448M88.2%30 / 5635 / 236M7M
Q1 202613049M90.7%24 / 4747 / 4714M10M
Q4 202515847M86.9%46 / 6031 / 168M9M
Q3 202512949M89.3%29 / 5821 / 1610M6M
Q2 202511645M82.5%28 / 3827 / 137M4M
Q1 202510242M76.7%102 / 00 / 042M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

121 funds held BBNX in Q2 2026, 31% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of BBNXValue% of fundAs of
Eventide Gilead Fund3,983,9177.33%$62.43M1.81%Jun 30, 2026
Eventide Healthcare & Life Sciences Fund2,052,1763.77%$32.16M1.80%Jun 30, 2026
Vanguard Total Stock Market Index Fund1,272,5042.34%$19.94M0.00%Jun 30, 2026
iShares Russell 2000 ETF1,062,5861.95%$16.65M0.02%Jun 30, 2026
Bruce Fund665,7001.22%$10.43M2.78%Jun 30, 2026
Vanguard Extended Market Index Fund469,6150.86%$7.36M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund445,4400.82%$5.71M0.02%Jul 31, 2026
iShares Russell 2000 Value ETF378,4330.70%$5.93M0.04%Jun 30, 2026
JPMorgan Small Cap Value Fund221,4500.41%$3.47M0.26%Jun 30, 2026
Fidelity Extended Market Index Fund208,9200.38%$2.53M0.01%May 31, 2026
Vanguard Russell 2000 Index Fund200,3440.37%$2.43M0.01%May 31, 2026
iShares U.S. Medical Devices ETF189,8970.35%$2.98M0.10%Jun 30, 2026
Schwab U.S. Small-Cap ETF188,9480.35%$2.29M0.01%May 31, 2026
Eventide Exponential Technologies Fund173,2980.32%$2.72M2.57%Jun 30, 2026
JPMorgan U.S. Small Company Fund126,7970.23%$1.99M0.18%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Sean SaintPresident & CEO, Director398,4290.73%Sep 4, 2026
Stephen FeiderChief Financial Officer159,3780.29%Nov 13, 2026
Mark HopmanChief Commercial Officer54,1430.10%Nov 4, 2026
Mike MensingerChief Product Officer174,7400.32%Oct 29, 2026
Steven Jon RussellChief Medical Officer207,6990.38%Sep 3, 2026
Christy JonesDirector19,5640.04%Sep 23, 2026
Danny L. DearenDirector32,2090.06%May 26, 2026
Sean CarneyDirector32,2090.06%May 26, 2026
Gerard J. MichelDirector33,5090.06%May 26, 2026
Maria PalasisDirector29,3970.05%May 26, 2026
Adam LezackDirector27,3990.05%May 26, 2026
Wellington Hadley Harbor Aggregator IV, L.P.10% owner3,901,5997.18%Feb 3, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Stephen Feider
Chief Financial Officer
Nov 11, 2026Sale(10b5-1 plan)−8,874$17.21$152.68K159,378
Stephen Feider
Chief Financial Officer
Nov 11, 2026Option exercise+8,874$5.10$45.26K168,252
Stephen Feider
Chief Financial Officer
Nov 9, 2026Sale(10b5-1 plan)−744$17.00$12.65K159,378
Stephen Feider
Chief Financial Officer
Nov 9, 2026Option exercise+744$5.10$3.79K160,122
Stephen Feider
Chief Financial Officer
Nov 5, 2026Sale(10b5-1 plan)−382$17.04$6.51K159,378
Stephen Feider
Chief Financial Officer
Nov 5, 2026Option exercise+382$5.10$1.95K159,760
Mark Hopman
Chief Commercial Officer
Nov 2, 2026Sale(10b5-1 plan)−370$16.90$6.25K54,143
Mike Mensinger
Chief Product Officer
Oct 27, 2026Sale(10b5-1 plan)−2,650$22.00$58.30K174,740
Mark Hopman
Chief Commercial Officer
Oct 26, 2026Sale(10b5-1 plan)−821$20.00$16.42K54,513
Mark Hopman
Chief Commercial Officer
Oct 14, 2026Sale(10b5-1 plan)−775$17.35$13.45K55,334
Mark Hopman
Chief Commercial Officer
Oct 1, 2026Sale(10b5-1 plan)−370$18.96$7.02K56,109
Christy Jones
Director
Sep 22, 2026Sale(10b5-1 plan)−6,430$23.00$147.89K19,564
Mark Hopman
Chief Commercial Officer
Sep 16, 2026Sale(10b5-1 plan)−30,779$20.13$619.58K56,479
Mike Mensinger
Chief Product Officer
Sep 16, 2026Sale(10b5-1 plan)−2,650$22.00$58.30K177,390
Mark Hopman
Chief Commercial Officer
Sep 14, 2026Sale(10b5-1 plan)−775$15.52$12.03K86,382
Mark Hopman
Chief Commercial Officer
Sep 9, 2026Sale(10b5-1 plan)−35,994$18.46$664.45K88,033
Mark Hopman
Chief Commercial Officer
Sep 9, 2026Sale(10b5-1 plan)−36,870$18.46$680.62K87,157
Sean Saint
President & CEO, Director
Sep 3, 2026Sale(10b5-1 plan)−5,641$20.08$113.27K398,429
Mark Hopman
Chief Commercial Officer
Sep 2, 2026Sale−5,327$19.11$101.80K124,027
Sean Saint
President & CEO, Director
Sep 2, 2026Sale−16,867$19.11$322.33K404,070
Stephen Feider
Chief Financial Officer
Sep 2, 2026Sale−6,675$19.11$127.56K159,378
Mike Mensinger
Chief Product Officer
Sep 2, 2026Sale−4,375$19.11$83.61K180,040
Steven Jon Russell
Chief Medical Officer
Sep 2, 2026Sale−4,221$19.11$80.66K169,628
Stephen Feider
Chief Financial Officer
Jun 29, 2026Sale(10b5-1 plan)−4,896$17.03$83.38K166,053
Stephen Feider
Chief Financial Officer
Jun 29, 2026Option exercise+4,896$5.10$24.97K170,949
Stephen Feider
Chief Financial Officer
Jun 29, 2026Option exercise+4,896$5.10$24.97K170,827
Stephen Feider
Chief Financial Officer
Jun 29, 2026Sale(10b5-1 plan)−4,896$17.03$83.38K165,931
Stephen Feider
Chief Financial Officer
Jun 26, 2026Sale(10b5-1 plan)−5,104$17.05$87.02K166,053
Stephen Feider
Chief Financial Officer
Jun 26, 2026Option exercise+5,104$5.10$26.03K171,157
Stephen Feider
Chief Financial Officer
Jun 26, 2026Sale(10b5-1 plan)−5,104$17.05$87.02K165,931
Stephen Feider
Chief Financial Officer
Jun 26, 2026Option exercise+4,982$5.10$25.41K171,035
Mark Hopman
Chief Commercial Officer
Jun 24, 2026Sale(10b5-1 plan)−1,258$15.01$18.88K129,354
Christy Jones
Director
Jun 24, 2026Sale(10b5-1 plan)−1,406$15.00$21.09K25,994
Christy Jones
Director
Jun 4, 2026Sale(10b5-1 plan)−2,811$14.00$39.35K27,400
Mark Hopman
Chief Commercial Officer
Jun 4, 2026Sale(10b5-1 plan)−275$12.31$3.39K130,612
Steven Jon Russell
Chief Medical Officer
Jun 2, 2026Sale−4,222$12.61$53.24K173,849
Stephen Feider
Chief Financial Officer
Jun 2, 2026Sale−6,676$12.61$84.18K166,053
Sean Saint
President & CEO, Director
Jun 2, 2026Sale−16,872$12.61$212.76K420,937
Mark Hopman
Chief Commercial Officer
Jun 2, 2026Sale−5,329$12.61$67.20K130,887
Mike Mensinger
Chief Product Officer
Jun 2, 2026Sale−4,378$12.61$55.21K184,415
Adam Lezack
Director
May 22, 2026Sale(10b5-1 plan)−998$11.21$11.19K27,399
Danny L. Dearen
Director
May 21, 2026Award+16,965––32,209
Christy Jones
Director
May 21, 2026Award+16,965––30,211
Christy Jones
Director
May 21, 2026Sale(10b5-1 plan)−1,998$9.95$19.88K13,246
Maria Palasis
Director
May 21, 2026Award+16,965––29,397
Adam Lezack
Director
May 21, 2026Award+16,965––28,397
Adam Lezack
Director
May 21, 2026Sale(10b5-1 plan)−1,000$9.95$9.95K11,432
Sean Carney
Director
May 21, 2026Award+16,965––32,209
Gerard J. Michel
Director
May 21, 2026Award+16,965––33,509
Mark Hopman
Chief Commercial Officer
Mar 4, 2026Sale(10b5-1 plan)−353$11.57$4.08K139,133
Mike Mensinger
Chief Product Officer
Mar 2, 2026Sale−1,064$12.36$13.15K188,793
Mark Hopman
Chief Commercial Officer
Mar 2, 2026Sale−834$12.36$10.31K139,486
Stephen Feider
Chief Financial Officer
Mar 2, 2026Sale−1,428$12.36$17.65K172,729
Steven Jon Russell
Chief Medical Officer
Mar 2, 2026Sale−1,026$12.36$12.68K179,096
Sean Saint
President & CEO, Director
Mar 2, 2026Sale−3,384$12.36$41.83K437,809
Mike Mensinger
Chief Product Officer
Feb 27, 2026Award+109,105––189,857
Mark Hopman
Chief Commercial Officer
Feb 27, 2026Award+109,105––140,320
Stephen Feider
Chief Financial Officer
Feb 27, 2026Award+131,543––174,157
Steven Jon Russell
Chief Medical Officer
Feb 27, 2026Award+109,105––180,122
Sean Saint
President & CEO, Director
Feb 27, 2026Award+343,269––441,193

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
10.10%
5M shares short
Days to cover
3.9
At 1M shares a day
Change since last report
-28.0%
From 7M shares
Short volume, 20 days
55.2%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Beta Bionics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 7,946 shares on Sep 18, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Stephen Feider
Officer
Nov 9, 2026744$12.65KNov 9, 2026Stock Options
Stephen Feider
Officer
Nov 5, 2026382$6.51KNov 5, 2026stock options
Mark Hopman
Officer
Oct 1, 20262,660$50.49KOct 1, 2026Exercise of Stock Options
Christina Jones
Director
Sep 22, 20268,942$197.08KSep 22, 2026Exercise of Stock Options
Michael Mensinger
Officer
Sep 16, 20265,300$101.92KSep 16, 2026Series D Purchase
Mark Hopman
Officer
Sep 16, 202628,119$540.73KSep 16, 2026Exercise of Stock Options
Mark Hopman
Officer
Sep 9, 202640,305$779.10KSep 9, 2026Exercise of Stock Options
Stephen Feider
Officer
Sep 3, 20266,675$129.60KSep 2, 2026Restricted Stock Units vesting under registered plan
Michael R. Mensinger
Officer
Sep 3, 20264,375$84.94KSep 2, 2026Restricted Stock Units vesting under registered plan
Steven Jon Russell
Officer
Sep 3, 20264,221$81.95KSep 2, 2026Restricted Stock Units vesting under registered plan
Mark Hopman
Officer
Sep 3, 20265,327$103.42KSep 2, 2026Restricted Stock Units vesting under registered plan
Sean Saint
Officer
Sep 3, 20265,641$113.26KSep 3, 2026Equity Award
Sean Saint
Officer, Director
Sep 3, 202616,867$327.47KSep 2, 2026Restricted Stock Units vesting under registered plan
Stephen Feider
Officer
Jun 29, 20264,896$83.38KJun 29, 2026Stock Options
Stephen Feider
Officer
Jun 26, 20265,104$87.01KJun 26, 2026Stock Options

See a number that looks wrong?